To the full analysis
Buyback calculator for Pacira BioSciences
Pacira BioSciences stock: key metrics
PCRXPacira BioSciences had an operating margin of 4.6% and a return on invested capital (ROIC) of 1.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | −25.4% | −325.8% | −300.6% |
| 2009 | 18.0% | −190.2% | −211.3% |
| 2010 | 15.7% | −153.6% | −186.4% |
| 2011 | −6.7% | −249.2% | −276.2% |
| 2012 | 17.8% | −126.1% | −133.8% |
| 2013 | 36.0% | −62.3% | −74.7% |
| 2014 | 60.8% | −2.6% | −6.9% |
| 2015 | 71.1% | 3.8% | 0.7% |
| 2016 | 60.2% | −11.6% | −13.7% |
| 2017 | 69.3% | −8.7% | −14.9% |
| 2018 | 74.3% | 4.7% | −0.1% |
| 2019 | 74.7% | 2.5% | −2.6% |
| 2020 | 72.7% | 10.8% | 33.9% |
| 2021 | 74.1% | 16.6% | 7.8% |
| 2022 | 70.1% | 9.0% | 2.4% |
| 2023 | 72.6% | 13.0% | 6.2% |
| 2024 | 75.7% | −10.5% | −14.2% |
| 2025 | 79.4% | 4.6% | 1.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | −100.0% | no data | −82.8% |
| 2009 | 138.2% | −71.5% | −72.1% |
| 2010 | 56.1% | −42.6% | −40.8% |
| 2011 | −89.8% | −43.5% | −38.2% |
| 2012 | −79.4% | −41.8% | −46.7% |
| 2013 | −100.0% | −71.7% | −37.6% |
| 2014 | −8.0% | −4.4% | −4.2% |
| 2015 | 0.8% | 5.9% | 0.5% |
| 2016 | −17.3% | −15.8% | −9.7% |
| 2017 | −15.2% | −9.9% | −6.8% |
| 2018 | −0.1% | 5.3% | −0.1% |
| 2019 | −3.1% | 2.6% | −1.3% |
| 2020 | 23.5% | 8.8% | 11.4% |
| 2021 | 5.7% | 7.3% | 2.0% |
| 2022 | 2.1% | 4.9% | 0.9% |
| 2023 | 4.8% | 4.9% | 2.7% |
| 2024 | −12.8% | −5.5% | −6.4% |
| 2025 | 1.0% | 1.8% | 0.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.